Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

163.66 +4.69 (+2.95%)
Official Closing Price Updated: 4:10 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session
Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results. 
Via Benzinga
Why Charles River Laboratories Stock Is Jumping Today
Investors liked the company's Q3 update. 
Via The Motley Fool
Expert Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Charles River: Q3 Earnings Insights
Charles River (NYSE:CRL) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Charles River beat estimated... 
Via Benzinga
Charles River Laboratories Announces Third-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
Medpace Earnings Are 'Almost Unbelievable'; MEDP Stock Flies
Medpace earnings soared in Q3 as weakness in contract awards turned to strength, sending MEDP stock surging. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
Charles River and Nanoscope Therapeutics Announce Multifaceted Gene Therapy Manufacturing Partnership
From Charles River Laboratories International, Inc.
Via Business Wire
5 Analysts Have This to Say About Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Charles River Laboratories Schedules Third-Quarter 2022 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs
From Charles River Laboratories International, Inc.
Via Business Wire
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Expert Ratings for Charles River
Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings: 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Where Charles River Stands With Analysts
Charles River (NYSE:CRL) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Charles River Q2 Earnings
  Charles River (NYSE:CRL) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022
Upgrades 
Via Benzinga
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock. 
Via Benzinga
Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River and Cure AP-4 Announce Gene Therapy Manufacturing Collaboration
From Charles River Laboratories International, Inc.
Via Business Wire
Charles River Laboratories Expands Contract Vivarium Space on West Coast
From Charles River Laboratories International, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades 
Via Benzinga
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading. 
Via Benzinga
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product
From Charles River Laboratories, International Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022
Upgrades 
Via Benzinga
AMD, SolarEdge Technologies And Some Other Big Stocks Moving Lower On Wednesday
  Rocky Brands, Inc. (NASDAQ: RCKY) dipped 21.6% to $26.62 after the company reported worse-than-expected Q2 EPS results. 
Via Benzinga
Charles River Laboratories Announces Second-Quarter 2022 Results
From Charles River Laboratories International, Inc.
Via Business Wire
'I'm Going To Have To Say Avoid It': Jim Cramer Urges Waiting Before Buying This Tech Stock
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Charles River Laboratories International Inc (NYSE: CRL). 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.